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Abstract
The clinical applicability of molecular cardiology has been questioned at length and by many
clinical investigators. The congenital long QT syndrome (LQTS) provides an excellent
example of how tight the relationship can be between molecular biology and clinical
cardiology. The advent of molecular diagnosis has demonstrated how low the penetrance
can be in LQTS; this implies that there are many gene carriers who do not show the clinical
phenotype and may have a normal QT interval despite being at risk. There is also a gene-
specific predisposition to be at risk for cardiac arrest under different circumstances, and this
provides additional basis for a gene-specific approach to therapy.
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Introduction
When the initial excitement for molecular biology settled
down, we all faced the same question: what about clinical
applicability? There are, as a matter of fact, numerous
examples of the clinical applicability of molecular biology
but one of the most impressive is certainly represented by
the leading cause of sudden death below age 20, namely
the congenital LQTS. Indeed, LQTS probably represents
the best example so far of how molecular biology can
modify the traditional clinical approach and allow a more
sophisticated clinical management tailored toward the spe-
cific, genetically controlled, characteristics of each patient.
This brief essay will first review the current information on
the LQTS genes and will then discuss how this new
wealth of knowledge is affecting the diagnostic and thera-
peutic process.
LQTS genes
Six loci have so far been related to LQTS, and five genes
have been identified. Two of these genes, KCNE1 and
Mirp1, respectively responsible for LQT5 and LQT6, are
rare. The most common forms, respectively responsible for
LQT1, LQT2, and LQT3, depend on mutations on
KvLQT1 (encoding the IKs current), on HERG (encodinghttp://cvm.controlled-trials.com/content/1/2/088
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the IKr current), and on SCN5A (encoding the Na+
current). The data available for genotype–phenotype cor-
relation studies on adequate numbers are limited to LQT1,
LQT2, and LQT3. A new terminology has therefore now to
be used in order not to miss these differences that are
important for a molecular understanding of the underlying
defects and mechanisms, and for a more specific and
effective clinical management [1–4].
Diagnosis
The cornerstone of the diagnosis of LQTS has always, and
dutifully so, been represented by the presence of a pro-
longed QT interval on the electrocardiogram. This was
always an integral part of the diagnostic criteria proposed
in 1985 [5] and later in 1993 [6]. It is true that, in 1980
[7] and then again in 1985 [5], it had already been pro-
posed that patients affected by LQTS who had a normal
QT interval must have existed. This unorthodox hypothesis
was received with skepticism and, despite growing sup-
portive data, was eventually proven correct when our
group provided conclusive evidence for low penetrance in
LQTS [8]. Penetrance represents the percentage of gene
carriers who show the clinical phenotype of any given
genetic disease. Penetrance for LQTS had been generally
assumed to be close to 90%, thus implying that very few
gene carriers could exist without showing the main clinical
characteristic, namely QT prolongation. We studied nine
genotyped probands who were considered ‘sporadic
cases of LQTS’ (ie no other member of these nine families
was thought to be affected by LQTS), and 46 family
members considered to be ‘non-affected’. Four of nine
probands proved to have de novo mutations, thus confirm-
ing the clinical impression that they were indeed ‘sporadic’
cases of LQTS. In the remaining five families, however,
several other members were found to be gene carriers.
Penetrance in these families ranged between 14 and
33%, thus suggesting that, at least in some families, there
are two to four additional individuals who are gene carriers
for each patient identified as clinically affected.
This finding has major clinical implications. When visiting
members of a LQTS family and, for example, when dis-
cussing with the parents of a truly affected child the clini-
cal status of some of his/her siblings with a normal QT
interval, it will no longer be possible to state, based on
clinical data alone, that they are ‘certainly not affected by
LQTS’. This has per se become a most important reason
to attempt genotyping in all LQTS probands (the proband
is the first family member seeking medical attention). In the
50–60% of patients in whom genotyping will be success-
ful (by current standards), it will become easy, fast, and
cheap to screen for the culprit mutation in all the remain-
ing family members. The silent gene carriers, who certainly
have a reduced ‘repolarization reserve’ [9], should avoid
conditions that produce hypokaliemia or drugs that block
IKr. This concept creates a novel responsibility for their
physicians, who should now alert these individuals to the
large number of drugs, cardiac and non-cardiac, that block
potassium currents.
Therapy
The recent realization that the arrhythmogenic ‘triggers’
(conditions associated with the onset of cardiac events,
such as syncope or cardiac arrest or sudden death) are, to
a large extent, gene specific will lead to specific manage-
ment strategies aimed at reducing the risk of major
cardiac events. The data come from a unique cooperative
effort [10] based on almost 700 patients of known geno-
type, and all with prior cardiac events. The same study
investigated the efficacy of beta-blockers.
Three main arrhythmogenic triggers were defined at the
outset of the study: exercise, emotions, and rest/sleep
without arousal. The analysis focused on the three major
subgroups, LQT1 (n = 371), LQT2 (n = 234), and LQT3
(n = 65), and striking differences emerged.
LQT1 patients had almost all of their events (88%) during
conditions associated with increased sympathetic activity,
especially during exercise (62%). When the analysis was
limited to lethal events, exercise accounted for 68% of the
patients. There is specificity also within the different types
of physical activity. Indeed, 33% of the cardiac events suf-
fered by LQT1 patients occurred while swimming. Con-
versely, 99% of the LQTS patients suffering cardiac
events while swimming did belong to the LQT1 subgroup.
Besides the direct clinical implications, this finding
strengthens the concept that reduction or block of the IKs
current predisposes to life-threatening arrhythmias under
conditions of increased sympathetic activity [11]. On this
basis, it follows that competitive sports should not be
allowed for LQT1 patients, and that they should avoid
strenuous exercise, with special attention to swimming.
It came as no surprise when this analysis was completed
that beta-blockers were particularly effective in this large
subgroup. Indeed, 81% of the patients had no recur-
rences once therapy was initiated. The incidence of
sudden death and resuscitated cardiac arrest was 4% in
the entire LQT1 population, and it was 23% among those
who had recurrences. Beta-blockers can clearly be
expected to be an effective and sufficient therapy for most
LQT1 patients.
The pattern shown by LQT2 and LQT3 patients was quite
different from that of LQT1 patients and showed unex-
pected similarities, particularly the relatively low incidence
of major cardiac events during exercise. These figures are
strikingly low when the analysis is limited to the lethal
events: none of the LQT2 and only 4% of the LQT3
patients died during exercise. A probable explanation lies
in the common feature shared by LQT2 and LQT3Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Schwartz
patients of a preserved IKs current. It is worth remembering
that IKs is activated by catecholamines, and facilitates
shortening of action potential duration when cycle length
shortens, a key factor in reducing the probability of re-
entrant arrhythmias.
LQT2 patients suffered most of their events during emo-
tions or while at rest. Their predisposition to suffer these
arrhythmic events in association with auditory stimuli, such
as those produced by telephone calls or alarm clocks,
especially when they are asleep, is of interest. This audi-
tory trigger accounts for 26% of the cardiac events for
LQT2 patients. Conversely, 80% of the events triggered
by acoustic stimuli occur in LQT2 patients. It follows that
removal of telephones and alarm clocks from the bed-
rooms of LQT2 patients could be considered as the sim-
plest, but nonetheless quite effective, of the gene-specific
therapies now available for patients affected by LQTS.
Beta-blockers are effective in LQT2 patients, but not so
strikingly as in LQT1 patients. Only 59% of the LQT2
patients had no more recurrences. Only 4% of the entire
group, however, suffered cardiac arrest and none suffered
sudden death. The combined incidence of cardiac arrest
and sudden death was 11% among the patients with
recurrences.
LQT3 patients are different, not only because they repre-
sent the most uncommon subtype of the three (not includ-
ing the rare LQT4, LQT5, and LQT6), but also because the
current affected is that carrying Na+ inside cardiac cells,
and because the consequence of most mutations is a ‘gain
of function’ resulting in an excess of delayed sodium
inward current. They are different because of a uniquely
high risk of sudden death during their first episode (20%
versus 4% among LQT1 and LQT2 patients) [12] and
because of additional clinical features disclosed by our
study of the genotype–phenotype correlation. The most
striking is the propensity of the LQT3 patients to have their
cardiac events while at rest or asleep without arousal. The
incidence of these events is 38% when syncope is
included, and reaches 62% when only lethal events are
considered. The underlying pathophysiologic mechanism is
represented by an excessive QT prolongation when cycle
length is prolonged; the best evidence of this phenomenon
is represented by the changes occurring during night-time
[13], when LQT3 patients have QTc prolongation that is
markedly prolonged compared with those observed among
LQT1 (almost absent) and LQT2 patients. Conversely, they
tend to shorten the QT interval during exercise much more
than the other two subgroups.
The outcome with beta-blockers within this group is also
not completely surprising, given the observations already
discussed. Clearly, LQT3 patients do not manage well
when their heart rate slows down. As this is a primary con-
sequence of treatment with beta-blockers, their question-
able efficacy could have been anticipated. Indeed, 56% of
the treated patients become asymptomatic and the inci-
dence of cardiac arrest and sudden death among treated
patients is very high (11% in the entire group and 25%
among those with recurrences). Indeed, left cardiac sympa-
thetic denervation as a means to prevent a major release of
norepinephrine at the ventricular level is recommended for
these patients. The implant of an implantable cardioverter-
defibrillator is also a very reasonable therapeutic option.
Because of the evidence that most mutations on SCN5A
lead to an excess of sodium inward current, the LQT3
patients represent the first group for which a gene-specific
(or, more precisely, a mutation-specific) therapy can be
implemented. Our group provided initial evidence in 1995
[14] that the sodium channel blocker mexiletine was able
to shorten the QT interval to a larger extent than in the
other subgroups. These data have been expanded and
confirm our initial impressions [15]. This finding may not
apply to all sodium channel blockers. Flecainide, for
example, has recently been suggested as a long-term
therapy for LQT3 patients. We have, however, recently
observed that when flecainide is administered intra-
venously to LQT3 patients, it not only shortened the QT
interval but also produced ST segment elevation in six of
13 patients in leads V1–V3, that are typical of the
Brugada syndrome [16]. This of course raises concerns
for its chronic use. Finally, it is important to remember that
there is no evidence whatsoever to indicate that the QT
shortening, albeit reassuring and encouraging, translates
into a clinical benefit for the patients.
Conclusion
Taken together, it seems unavoidable to admit and recog-
nize that molecular biology does indeed have clinical
applicability, and that the long QT syndrome represents a
prime example of this concept.
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